Incyte Corp

19 oct. 2026, 19:36 UTC

Incyte Corp will present new data on investigational therapies INCB161734 and INCA33890 at the ESMO Congress 2026, scheduled for October 23 to 27 in Madrid.

17 oct. 2026, 00:01 UTC

Incyte Corp shares are trading lower in after-market hours, reversing an initial gain and reaching their lowest point of the day.

16 oct. 2026, 20:13 UTC

Incyte Corp shares are modestly higher in after-market trading, maintaining a slight gain.

15 oct. 2026, 21:03 UTC

Incyte Corp shares are advancing in after-market trading, continuing a strong performance after three consecutive sessions of gains, though still below the 20-day moving average.

14 oct. 2026, 20:07 UTC

Truist Securities maintains Hold rating on Incyte Corp and raises price target to $115 in a report published today.

13 oct. 2026, 20:02 UTC

Incyte Corp shares fell sharply, reaching a low point shortly after the market opened and remaining below its 20-day moving average.

12 oct. 2026, 21:01 UTC

Incyte Corp shares declined in after-market trading, continuing a downward trend and remaining notably below its 20-day moving average.

9 oct. 2026, 20:07 UTC

Incyte Corp shares traded roughly flat, peaking at a cumulative return of 0.90%, but remain significantly below their 20-day moving average.

8 oct. 2026, 20:07 UTC

RBC Capital raised Incyte's price target to $114 and maintained its Sector Perform rating ahead of the company's Q3 results on October 29, 2026.

7 oct. 2026, 21:31 UTC

Incyte Corp is trading lower in after-market hours, closing at its lowest point of the day and below its 20-day moving average.

6 oct. 2026, 19:50 UTC

Incyte Corp shares fell sharply, extending a six-session decline amid notable volatility, with current prices significantly below the 20-day moving average.

5 oct. 2026, 21:01 UTC

Incyte Corp is down significantly in after-market trading, marking its seventh consecutive session lower and remaining well below its 20-day moving average.

2 oct. 2026, 23:05 UTC

Incyte Corp saw a modest increase in after-market trading, reaching its highest level since Friday's close, despite notable volatility during the session.

1 oct. 2026, 23:15 UTC

Incyte Corp declined in after-market hours, marking its fourth consecutive session of losses and remaining significantly below its 20-day moving average.

30 sept. 2026, 20:01 UTC

Incyte Corp shares fell sharply, remaining below their 20-day moving average and positioned near the lower end of their one-month range.

29 sept. 2026, 20:07 UTC

Incyte Corp's shares fell sharply, reaching a midday low and finishing weaker, remaining below their 20-day moving average and near the lower end of their one-month trading range.

28 sept. 2026, 21:01 UTC

Incyte Corp has advanced in after-market trading, reaching its highest level for the session amid broader biotechnology sector activity and remaining above its 20-day moving average.

25 sept. 2026, 19:36 UTC

Incyte shares fell after FDA approved Atebrioz for fibrodysplasia ossificans progressiva, as traders await clarity on the drug's commercial prospects.

24 sept. 2026, 22:01 UTC

Incyte Corp declined significantly in after-market trading, remaining well below its 20-day moving average and near the lower end of its one-month range.

23 sept. 2026, 20:07 UTC

Incyte Corp shares are declining, despite social media highlighting its strength in the biotechnology sector, reflecting a cumulative decline since Tuesday's close.

22 sept. 2026, 23:45 UTC

Incyte Corp is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

21 sept. 2026, 20:06 UTC

Incyte Corp's shares are declining despite announcing an expanded partnership with Specialised Therapeutics to commercialize ruxolitinib cream in Australia.

18 sept. 2026, 22:51 UTC

Incyte Corp is trading modestly higher in after-market hours, reflecting broader market trends amid mixed equity performance and rising treasury yields.

17 sept. 2026, 23:26 UTC

Incyte Corp's stock is trading higher in after-market hours as investors await an FDA decision on zilurgisertib, with a target date of September 26.

16 sept. 2026, 23:06 UTC

Incyte Corp is trading lower in after-market hours, marking its lowest point since the market closed and remaining below its 20-day moving average.

15 sept. 2026, 23:06 UTC

Incyte Corp shares are trading lower in after-market hours, reflecting broader market fluctuations and remaining below the 20-day moving average.

14 sept. 2026, 20:08 UTC

Incyte Corp's shares are higher amid overall market gains, despite earlier volatility. Broader market concerns include rising crude oil prices and inflation.

11 sept. 2026, 22:01 UTC

Incyte Corp shares are higher in after-market trading, despite a decline in consumer sentiment reflected by the Michigan Consumer Sentiment Index.

10 sept. 2026, 19:36 UTC

Incyte's MINJUVI receives funding in Ontario for lymphoma treatment. Shares are lower despite this development, currently trading below their 20-day moving average.

9 sept. 2026, 19:07 UTC

Incyte Corp gains amid positive sentiment for its upcoming PDUFA date for Zilurgisertib, scheduled for September 26, despite earlier session volatility.